Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

Novavax Inc. closed 61.03% short of its 52-week high of $17.81, which the company achieved on July 26th.

The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...

The RSV shot, mRESVIA, secured U.S. approval on Thursday for expanded use in at-risk adults aged 18 to 59 years, but needs ...

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

The data showed that both the CIC and flu vaccine candidates induced immune responses similar to licensed comparators ...